Telly Purnamasari
Pusat Teknologi Terapan Kesehatan dan Epidemiologi Klinik, Badan Litbangkes Kementerian Kesehatan

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

PERBANDINGAN EFEKTIFITAS DOSIS SEKALI MINUM ARTEMISININ-NAFTOKUIN DENGAN DIHIDROARTEMISININ-PIPERAKUIN PADA PENGOBATAN PASIEN DEWASA MALARIA FALSIPARUM TANPA KOMPLIKASI Siswantoro, Hadjar; Hasugian, Armedy Ronny; Purnamasari, Telly; Laning, Sri; Yanuar, Lidwina; Dedang, Tersila; Tjitra, Emiliana
Media Penelitian dan Pengembangan Kesehatan Vol 24, No 3 Sep (2014)
Publisher : Badan Penelitian dan Pengembangan Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (564.468 KB)

Abstract

AbstrakKombinasi pengobatan berbasis artemisinin yang praktis dan sederhana dengan kepatuhan minum obat yang baik telah ditunjukkan dalam artikel utama: “Efficacy and Safety of Artemisinin-naphthoquine versus  dihydroartemisinin-piperaquine  in  adult  patients  with  uncomplicated  malaria:  a  multi-centre study in Indonesia” pada pasien dewasa dengan malaria apapun. Untuk melengkapi data terdahulu, disajikan  data  keamanan  dan  efikasi  obat  sekali  minum  artemisinin-naftokuin  (ANT)  dibandingkan dihidroartemisinin-piperakuin  (DHP)  pada  pengobatan  pasien  dewasa  dengan  malaria  falsiparum. Tujuan penelitian ini adalah untuk membandingkan efikasi dan keamanan antara ANT dengan DHP pada pasien dewasa dengan malaria falsiparum. Studi dilakukan dengan uji klinik fase III, acak, terbuka menggunakan amplop terbuka, menggunakan protokol who untuk menilai efikasi obat antimalaria yang dipantau selama 42 hari. Hasil penelitian menunjukkan efikasi ANT dan DHP pada hari ke-42 berturutturut adalah 100% (74/74) dan 97,1% (66/68) dengan 2,9% (2/68) mengalami kegagalan pengobatan kasep.  Kejadian  sampingan  adalah  2,5%  batuk  setelah  pengobatan  ANT,  dan  1,4%  batuk  setelah pengobatan  DHP.  Kesimpulan  yang  diambil ANT  dosis  tunggal  aman  dan  efektif  seperti  DHP  dosis tunggal harian selama 3 hari untuk pengobatan malaria falsiparum dewasa tanpa komplikasi.Kata  kunci:  malaria,  dihidroartemisinin-piperakuin,  artemisinin-naftokuin,  Plasmodium  falciparum, Indonesia.AbstractA practical and simple Artemisinin based combination  therapy (ACT) with good compliance  in adult patients for all malaria species has been shown in the first article: “Efficacy and Safety of Artemisininnaphthoquine  versus  dihydroartemisinin-piperaquine  in  adult  patients  with  uncomplicated  malaria:  a multi-centre study in Indonesia”. It is worth to add data safety and efficacy of single dose artemisininnaphthoquine  (ANT)  compared  with  dihydroartemisinin-piperaquine  (DHP)  in  adult  patients  with P.falciparum malaria. The aims of this study is to compare safety and efficacy of ANT with DHP in adult patients  with  uncomplicated  P.falciparum  malaria. this  study  is  a  clinical  trial  phase  III,  randomized, open-label using unsealed envelopes, using WHO protocol to measure efficacy of antimalaria drug with 42 days of follow-up. The results show the efficacy of ANT and DHP at day 42 was 100% (74/74) and 97.1% (66/68), respectively with 2.9% (2/68) late treatment of failure for DHP. Adverse event was 2.5% cough after ANT treatment, and 1.4% cough after DHP treatment. The conclusion is that single dose of ANT is safe and very effective similar with DHP single daily dose for three days for treatment adult patients with uncomplicated P.falciparum malaria.Keywords : malaria, dihydroartemisinin-piperaquine, artemisinin-naphthoquine, Plasmodium falciparum, Indonesia.
The role of changes in metabolic syndrome status on health-related quality of life in Bogor City, West Java, Indonesia: A cross-sectional study Indriyati, Titi; Adisasmita, Asri C.; Nadjib, Mardiati; Subekti, Imam; Hatma, Ratna Djuwita; Kosen, Soewarta; Riyadina, Woro; Purnamasari, Telly
Belitung Nursing Journal Vol. 11 No. 2 (2025): March - April
Publisher : Belitung Raya Foundation, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33546/bnj.3543

Abstract

Background: Metabolic syndrome (MetS) is a cluster of chronic conditions, including central obesity, hypertension, impaired glucose metabolism, and dyslipidemia (low HDL, high LDL, and triglycerides). A diagnosis of MetS is made when three or more of these symptoms are present. If left unmanaged, MetS can lead to serious health complications such as cardiovascular disease and type 2 diabetes. Over time, individuals with MetS may experience a decline in their health-related quality of life (HRQoL), especially due to its chronic nature. Objective: This study aimed to evaluate the effects of changes in MetS status on HRQoL. Methods: This study employed a cross-sectional design. Secondary data from the cohort study of Non-Communicable Disease (NCD) risk factors, conducted by the Health Research and Development Agency of the Ministry of Health of the Republic of Indonesia in Bogor City, was used. Data from four follow-up periods (2011/2012 to 2017/2018) were analyzed. A total of 874 respondents were selected via total sampling based on inclusion and exclusion criteria. Data were collected in 2021, which included measures of knowledge, health check-ups, and HRQoL using the SF-36 questionnaire. Statistical analyses, including chi-square tests, t-tests, and multiple regression analyses, were conducted to examine the associations between MetS status and HRQoL. Results: Descriptive analysis revealed that 19% (171 participants) had worsened MetS status, while 80.4% (703 participants) showed improvement. Chi-Square analysis found that respondents with worsening MetS status were 1.6 times more likely to experience poor HRQoL in the physical dimension (95% CI = 1.1-2.3), but no significant effect was found for the mental dimension (PR = 1.1, 95% CI = 0.8-1.6). Multiple logistic regression analysis revealed that comorbidities interacted with worsening MetS status to significantly affect HRQoL in the physical dimension. The adjusted prevalence ratios (PR) were 27.5 (95% CI = 10.3-73.2) for those with comorbidities and 9.2 (95% CI = 5.7-15.0) for those without comorbidities, after controlling for age, mental health, BMI changes, routine health checks, and knowledge. Conclusion: Changes in MetS status towards worsening have a significant negative effect on HRQoL, particularly in the physical dimension. The presence of comorbidities in individuals with worsening MetS status greatly increases the risk of poor HRQoL. Healthcare professionals and nurses should consider the interaction between MetS and comorbidities in patient management. Nurses are encouraged to monitor HRQoL in patients with MetS, promote education on managing comorbidities, and collaborate across disciplines to enhance patient care and intervention programs aimed at improving HRQoL.